Sat Kartar

How has been the historical performance of the Sat Kartar?

Sat Kartar reported a profit before tax of Rs 8.00 crore for the year ending March 2024, with a net cash inflow of Rs 1.00 crore, resulting in a closing cash balance of Rs 2.00 crore despite cash outflows from investing and financing activities.

Answer:<BR>The historical performance of Sat Kartar shows a profit before tax of Rs 8.00 crore for the year ending March 2024. After accounting for adjustments of Rs 1.00 crore, the cash flow after changes in working capital stands at Rs 10.00 crore. The cash flow from operating activities is recorded at Rs 7.00 crore, while cash flow from investing and financing activities both show outflows of Rs 2.00 crore each. This results in a net cash inflow of Rs 1.00 crore, leading to a closing cash and cash equivalent balance of Rs 2.00 crore.<BR><BR>Breakdown:<BR>In the standalone cash flow results for March 2024, Sat Kartar reported a profit before tax of Rs 8.00 crore, with adjustments bringing the cash flow after changes in working capital to Rs 10.00 crore. The cash flow from operating activities was positive at Rs 7.00 crore, indicating healthy operational performance. However, the company experienced cash outflows from both investing and financing activities, each amounting to Rs 2.00 crore. Despite these outflows, Sat Kartar achieved a net cash inflow of Rs 1.00 crore, resulting in a closing cash and cash equivalent balance of Rs 2.00 crore, reflecting a modest liquidity position.

Who are the top shareholders of the Sat Kartar?

The top shareholders of Sat Kartar include Ajooni Wellness Private Limited with 36.28%, eight Foreign Institutional Investors holding 6.31%, and Shreya Jain as the highest public shareholder at 3.56%. Individual investors own 17.81% of the shares, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Sat Kartar include Ajooni Wellness Private Limited, which holds the highest stake at 36.28%. Additionally, there are eight Foreign Institutional Investors (FIIs) collectively holding 6.31% of the company. The highest public shareholder is Shreya Jain, with a holding of 3.56%. Individual investors collectively own 17.81% of the shares. There are no pledged promoter holdings, and no mutual funds are currently holding shares in the company.

What does Sat Kartar do?

Sat Kartar Shopping Ltd, a Micro Cap company in the Pharmaceuticals & Biotechnology sector, was incorporated in 2012 and became a public company in 2021. It currently has a market cap of Rs 304 Cr, with no available revenue or profit data for the latest quarter.

Overview:<BR>Sat Kartar Shopping Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated in 2012 as "Sat Kartar Shopping Private Limited" and later converted to a Public Limited Company, changing its name to Sat Kartar Shopping Limited on July 12, 2021. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: Rs 304 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 30.00<BR>Industry P/E: 35<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.00<BR>Return on Equity: 0.00%<BR>Price-to-Book: 0.00<BR><BR>Contact Details:<BR>Registrar Address: Not available.

When is the next results date for Sat Kartar?

No Upcoming Board Meetings

Has Sat Kartar declared dividend?

No Dividend History Available

Who are the peers of the Sat Kartar?

The peers of Sat Kartar include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Sun Pharma, Cipla, and Dr Reddy's Labs show excellent management and growth, while Divi's Lab has the highest 1-year return at 51.88%, and Sat Kartar's return is 0.00%.

Peers: The peers of Sat Kartar are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Natural Capsules, Coral Labs., Kimia Bioscien., Pharmaids Pharma, and Balaxi Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Balaxi Pharma, while Below Average management risk is found at Natural Capsules, Coral Labs., Kimia Bioscien., Pharmaids Pharma, and the rest. Growth is Excellent for Sat Kartar, Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Balaxi Pharma, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Kimia Bioscien., and Pharmaids Pharma, and the rest. Excellent capital structure is seen at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Balaxi Pharma, while Good capital structure is noted for Torrent Pharma and Natural Capsules, and Below Average capital structure is found at Kimia Bioscien., Pharmaids Pharma, and the rest.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.88%, while Natural Capsules has the lowest at -20.72%. Sat Kartar's own 1-year return is 0.00%, which is lower than both of these peers. Additionally, the six-month return is negative for Natural Capsules, Coral Labs., and Kimia Bioscien.

How big is Sat Kartar?

As of 24th July, Sat Kartar Shopping Ltd has a market capitalization of 274.00 Cr and is classified as a Micro Cap. There is no valid financial data available for recent net sales, net profit, or balance sheet metrics.

As of 24th July, <BR><BR>Market Cap: Sat Kartar Shopping Ltd has a market capitalization of 274.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: There is no valid balance sheet data available for the latest annual period, including values for Shareholder's Funds and Total Assets.

Is Sat Kartar overvalued or undervalued?

As of October 7, 2025, Sat Kartar is considered fairly valued with a PE ratio of 24.36, an EV to EBITDA of 15.07, and a ROE of 19.07%, making it an attractive investment compared to peers despite a recent 1-month return of -9.55%.

As of 7 October 2025, the valuation grade for Sat Kartar has moved from very attractive to attractive, indicating a shift in market perception. The company is currently considered fairly valued. Key ratios include a PE ratio of 24.36, an EV to EBITDA of 15.07, and a ROE of 19.07%. <BR><BR>In comparison to peers, Sat Kartar's PE ratio is lower than Sun Pharma's 34.6 and Divi's Lab's 70.24, which are considered expensive, while it is higher than Cipla's 22.68 and Dr. Reddy's Labs' 18.37, both of which are attractive. Despite the recent underperformance with a 1-month return of -9.55% compared to the Sensex's 1.48%, the company's strong fundamentals suggest it remains a solid investment within the pharmaceuticals and biotechnology sector.

Why is Sat Kartar Shopping Ltd falling/rising?

As of 02-Apr, Sat Kartar Shopping Ltd's stock price is at 167.35, reflecting a 5.92% increase and outperforming the Sensex by 6.75% today. Despite a decrease in investor participation, the stock shows strong relative performance and positive short-term trends.

As of 02-Apr, Sat Kartar Shopping Ltd's stock price is rising, currently at 167.35, which reflects an increase of 9.35 or 5.92%. This upward movement can be attributed to its strong performance relative to the benchmark, as it has outperformed the Sensex by 6.75% today. Over the past week, the stock has increased by 3.30%, while the Sensex has declined by 2.55%. Additionally, the year-to-date performance shows a significant gain of 17.03% for the stock compared to a loss of 13.08% for the Sensex. <BR><BR>Despite a decrease in investor participation, with delivery volume falling by 6.25% against the 5-day average, the stock remains liquid enough for trading. The current price is also higher than the 5-day, 20-day, 50-day, and 100-day moving averages, indicating a positive trend in the short to medium term, although it is lower than the 200-day moving average. Overall, the combination of strong relative performance and positive short-term trends contributes to the rising stock price of Sat Kartar Shopping Ltd.

Which are the latest news on Sat Kartar?